KR20240152875A - L-트립토판, l-5-하이드록시트립토판 및 말초 분해 억제제를 포함하는 약학 조성물 및 약제 - Google Patents

L-트립토판, l-5-하이드록시트립토판 및 말초 분해 억제제를 포함하는 약학 조성물 및 약제 Download PDF

Info

Publication number
KR20240152875A
KR20240152875A KR1020247030751A KR20247030751A KR20240152875A KR 20240152875 A KR20240152875 A KR 20240152875A KR 1020247030751 A KR1020247030751 A KR 1020247030751A KR 20247030751 A KR20247030751 A KR 20247030751A KR 20240152875 A KR20240152875 A KR 20240152875A
Authority
KR
South Korea
Prior art keywords
tryptophan
hydroxytryptophan
peripheral
medicament
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247030751A
Other languages
English (en)
Korean (ko)
Inventor
요아힘 캄프라드
Original Assignee
요아힘 캄프라드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 요아힘 캄프라드 filed Critical 요아힘 캄프라드
Publication of KR20240152875A publication Critical patent/KR20240152875A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
KR1020247030751A 2022-02-16 2023-02-08 L-트립토판, l-5-하이드록시트립토판 및 말초 분해 억제제를 포함하는 약학 조성물 및 약제 Pending KR20240152875A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102022103658.8 2022-02-16
DE102022103658.8A DE102022103658A1 (de) 2022-02-16 2022-02-16 Arzneimittelzusammensetzung enthaltend L-Tryptophan (L-Try) und L-5-Hydroxytryptophan (5-HTP) sowie einen peripheren Abbauhemmer
PCT/EP2023/053129 WO2023156275A1 (en) 2022-02-16 2023-02-08 Pharmaceutical composition and medicament comprising l-tryptophan, l-5-hydroxytryptophan and a peripheral degradation inhibitor

Publications (1)

Publication Number Publication Date
KR20240152875A true KR20240152875A (ko) 2024-10-22

Family

ID=85221827

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247030751A Pending KR20240152875A (ko) 2022-02-16 2023-02-08 L-트립토판, l-5-하이드록시트립토판 및 말초 분해 억제제를 포함하는 약학 조성물 및 약제

Country Status (10)

Country Link
US (1) US20250161270A1 (cg-RX-API-DMAC10.html)
EP (1) EP4479027A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025505294A (cg-RX-API-DMAC10.html)
KR (1) KR20240152875A (cg-RX-API-DMAC10.html)
CN (1) CN118871096A (cg-RX-API-DMAC10.html)
AU (1) AU2023222362A1 (cg-RX-API-DMAC10.html)
CA (1) CA3243635A1 (cg-RX-API-DMAC10.html)
DE (1) DE102022103658A1 (cg-RX-API-DMAC10.html)
MX (1) MX2024009966A (cg-RX-API-DMAC10.html)
WO (1) WO2023156275A1 (cg-RX-API-DMAC10.html)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4126672A (en) 1976-02-04 1978-11-21 Hoffmann-La Roche Inc. Sustained release pharmaceutical capsules
US4167558A (en) 1976-02-13 1979-09-11 Hoffmann-La Roche Inc. Novel sustained release tablet formulations
US4140755A (en) 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
CH652025A5 (de) 1981-09-14 1985-10-31 Hoffmann La Roche Pharmazeutisches praeparat.
DE3642668A1 (de) 1986-12-13 1988-06-23 Kamprad Joachim Schmerzmittel fuer menschen
FR2654931B1 (fr) 1989-11-24 1993-08-27 Trouillas Paul Compositions pharmaceutiques possedant une activite sur l'ataxie et les troubles de l'equilibre, cerebelleux ou autres, de toutes origines, comprenant l'association de l-5-hydroxytryptophane et de carbidopa.
US6207699B1 (en) * 1999-06-18 2001-03-27 Richard Brian Rothman Pharmaceutical combinations for treating obesity and food craving
EP1751312A4 (en) * 2004-05-21 2010-01-27 Univ Duke POLYMORPHISM IN TRYPTOPHAN HYDROXYLASE 2 REGULATING BRAIN SEROTONIN SYNTHESIS
DE102004039196B4 (de) 2004-08-12 2008-07-31 Dr.Kamprad Kg Neue Formulierung für L-Tryptophan
US20060257469A1 (en) * 2005-04-05 2006-11-16 Bulka Yochanan R Enhanced indoleamine and catecholamine bio-availability via catechin inhibition of L-Dopa decarboxylase
ES2948788T3 (es) * 2018-01-29 2023-09-19 Univ Duke Composiciones y métodos para mejorar la biodisponibilidad del 5-hidroxitriptófano

Also Published As

Publication number Publication date
JP2025505294A (ja) 2025-02-21
WO2023156275A1 (en) 2023-08-24
CA3243635A1 (en) 2023-08-24
DE102022103658A1 (de) 2023-08-17
EP4479027A1 (en) 2024-12-25
AU2023222362A1 (en) 2024-09-12
CN118871096A (zh) 2024-10-29
US20250161270A1 (en) 2025-05-22
MX2024009966A (es) 2024-11-08

Similar Documents

Publication Publication Date Title
KR102795284B1 (ko) 베타-히드록시부티레이트 및 부탄디올의 s-거울상이성질체 및 이의 사용 방법
JP2572768B2 (ja) レボドパメチルエステルを有効成分とするパ−キンソン病治療剤
JP2001513487A (ja) 糖尿病治療用組成物及び治療方法
CA2711809A1 (en) Compositions and methods for increasing muscle mass, strength, and functional performance in the elderly
US9427419B2 (en) Compositions comprising dimethyl sulfoxide (DMSO)
JPWO2004019928A1 (ja) 肝疾患治療剤
JP2024019691A (ja) 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法
Stocchi The hypothesis of the genesis of motor complications and continuous dopaminergic stimulation in the treatment of Parkinson's disease
JP2004534094A (ja) 二日酔いに有効な組成物及びそのための使用
ZA200700395B (en) Novel formulation for L-tryptophane comprising carbidopa/benserazide
CN104667283B (zh) 一种治疗血脂异常和动脉粥样硬化的复方药物组合
EP2723448A1 (en) Compositions and methods for treatment of chronic fatigue
Maddrey Branched chain amino acid therapy in liver disease.
AU750645B2 (en) Composition comprising L-carnitine or an alkanoyl L-carnitine and NADH and/or NADPH
US20110117070A1 (en) Compositions and methods for treating headache
JPH07233070A (ja) 疲労改善剤
EP4479027A1 (en) Pharmaceutical composition and medicament comprising l-tryptophan, l-5-hydroxytryptophan and a peripheral degradation inhibitor
KR100725263B1 (ko) ＨＭＧ-ＣｏＡ 리덕타제 억제제 및 카르니틴을 포함하는 항지질혈성 복합제
CN100408038C (zh) 用来治疗原发性头痛的复合维生素的应用
JP2000128784A (ja) 二日酔い症状
Bowers et al. 5-Hydroxytryptophan (5-hydroxy-L-tryptophan, L-5-hydroxytryptophan, oxitriptan)
JP2025505294A5 (cg-RX-API-DMAC10.html)
Bowers et al. L-5-Hydroxytryptophan, Oxitriptan
JP2004002452A (ja) アルコール性肝障害予防用組成物
HK1036589A (en) Composition comprising l-carnitine or an alkanoyl l-carnitine and nadh and/or nadph

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000